Dr. Reddy's Laboratories/$RDY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
- Ticker
- $RDY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 27,527
- Headquarters
- Hyderabad, India
- Website
- www.drreddys.com
RDY Metrics
BasicAdvanced
$10B
29.65
$0.41
0.24
$0.06
0.52%
Price and volume
Market cap
$10B
Beta
0.24
52-week high
$15.67
52-week low
$11.36
Average daily volume
2.9M
Dividend rate
$0.06
Financial strength
Current ratio
1.902
Quick ratio
1.161
Long term debt to equity
0.031
Total debt to equity
0.186
Dividend payout ratio (TTM)
20.11%
Interest coverage (TTM)
8.46%
Profitability
EBITDA (TTM)
569.005
Gross margin (TTM)
50.18%
Net profit margin (TTM)
10.00%
Operating margin (TTM)
10.63%
Effective tax rate (TTM)
20.77%
Revenue per employee (TTM)
$125,110
Management effectiveness
Return on assets (TTM)
4.02%
Return on equity (TTM)
8.84%
Valuation
Price to earnings (TTM)
29.654
Price to revenue (TTM)
2.962
Price to book
2.61
Price to tangible book (TTM)
3.74
Price to free cash flow (TTM)
77.031
Free cash flow yield (TTM)
1.30%
Free cash flow per share (TTM)
0.159
Dividend yield (TTM)
0.52%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
-0.92%
Earnings per share change (TTM)
-41.68%
3-year revenue growth (CAGR)
8.25%
10-year revenue growth (CAGR)
8.36%
3-year earnings per share growth (CAGR)
-11.21%
10-year earnings per share growth (CAGR)
8.49%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about RDY
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
Analyst projections of the future price of Dr. Reddy's Laboratories stock.
Bulls say / Bears say
The base business is growing despite the US decline: India revenue rose 17% and emerging-markets revenue rose 31% in Q1. Branded businesses made up 52% of revenue, while the company held a net cash surplus, giving it greater resilience and funding flexibility. (StockTitan, Dr. Reddy's Laboratories)
FDA approval of the company’s rituximab biosimilar opens the US market through exclusive commercialisation by Fresenius Kabi. Management also continues to target December approval for intravenous abatacept, supporting a longer-term move into biosimilars and higher-value medicines. (StockTitan, Webull)
Q1 revenue fell 5.6% and the company booked a ₹2.397bn provision after out-of-specification semaglutide batches. Commercial supplies are delayed until at least November, which puts a high-growth product and near-term margins at risk. (StockTitan, StockTitan)
North American revenue fell 35% in Q1 as lenalidomide sales declined, while management said US price erosion means new launches must compensate. This makes earnings more dependent on a steady pipeline of successful launches. (Dr. Reddy's Laboratories, Webull)
Recent FDA inspections produced seven observations at the biologics facility and four at the FTO-3 formulations plant. Although Dr. Reddy’s says it will address them, unresolved findings could delay biologics approvals or disrupt future supply. (StockTitan, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
RDY Financial Performance
Revenues and expenses
RDY Earnings Performance
Company profitability
Upcoming events
No upcoming events
RDY News
AllArticlesVideos
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Reuters3 weeks ago
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire2 months ago
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Business Wire2 months ago
Funds containing RDY
AllEURGBP
Fund name | Fund size | $RDY weighting |
|---|---|---|
Invesco FTSE All-World€FWIA | €4B | 0.09% |
Invesco FTSE All-World£FWRG | £3.4B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.